Genovate Biotechnology Co., Ltd.

TPEX:4130 Stock Report

Market Cap: NT$2.5b

Genovate Biotechnology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Genovate Biotechnology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth59.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years

Mar 09
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years

Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?

Feb 10
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?

Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals

Jan 04
Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals

How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 08
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genovate Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4130 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024523276392N/A
3/31/2024536331952N/A
12/31/2023529295185N/A
9/30/2023524301648N/A
6/30/202350321-1317N/A
3/31/202347110-1113N/A
12/31/2022439-12-232N/A
9/30/20224363933N/A
6/30/2022439-12-317N/A
3/31/2022430-18-135N/A
12/31/20214340-35-17N/A
9/30/2021413-10-152N/A
6/30/202141712525N/A
3/31/202144029637N/A
12/31/2020473396087N/A
9/30/2020487435080N/A
6/30/2020476322356N/A
3/31/2020466296290N/A
12/31/2019466341644N/A
9/30/201947039-626N/A
6/30/2019467631339N/A
3/31/201946458937N/A
12/31/2018456582663N/A
9/30/2018443965691N/A
6/30/2018439984887N/A
3/31/2018434158N/A39N/A
12/31/2017408149N/A31N/A
9/30/2017412112N/A16N/A
6/30/201742090N/A50N/A
3/31/201741429N/A93N/A
12/31/201641139N/A71N/A
9/30/201643941N/A59N/A
6/30/201644349N/A41N/A
3/31/201645251N/A52N/A
12/31/201547846N/A33N/A
9/30/201545444N/A70N/A
6/30/201546752N/A73N/A
3/31/201547970N/A85N/A
12/31/201447573N/A111N/A
9/30/201446473N/A86N/A
6/30/201444363N/A95N/A
3/31/201441956N/A65N/A
12/31/201339746N/A121N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4130's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4130's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4130's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4130's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4130's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4130's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y